BIOXYNE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.007 AUD | +16.67% |
|
0.00% | -36.36% |
| 05-14 | Bioxyne to Release Shares from Escrow; Shares Up 17% | MT |
| 05-14 | Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Bioxyne Limited is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries Japan, Australia, the United Kingdom, and Czechia. The Company direct sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -36.36% | 9.49M | |
| +29.51% | 49.18B | |
| +0.65% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.69% | 26.09B | |
| -22.68% | 18.71B | |
| +8.04% | 13.26B | |
| +32.55% | 12.32B | |
| -1.50% | 11.99B |
- Stock Market
- Equities
- BXN Stock
- News Bioxyne Limited
- Bioxyne Proceeds With Breathe Life Sciences Acquisition; Shares Fall 4%
